Completed PHASE1 INTERVENTIONAL 7-arm NCT01473173

Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study, to Investigate the Safety, Tolerability, PK and PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects

Sponsor: HK inno.N Corporation

Conditions Healthy

Interventions CJ-12420 Esomeprazole 40mg

Updated 7 times since 2017 Last updated: Apr 9, 2013 Started: Nov 30, 2011 Primary completion: Aug 31, 2012 Completion: Aug 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01473173, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by HK inno.N Corporation, it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Aug 2020 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Jun 2018 — Aug 2020 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

HK inno.N Corporation

Data source: HK inno.N Corporation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea